Literature DB >> 7981182

Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus.

J D Bagdade1, F L Dunn, R H Eckel, M C Ritter.   

Abstract

Patients with insulin-dependent diabetes mellitus (IDDM) have proatherogenic disturbances in cholesteryl ester transfer (CET) despite intensive subcutaneous insulin therapy (ISC). Since CET is activated by insulin-sensitive lipoprotein lipase (LPL), which normally increases postprandially, we queried whether iatrogenic hyperinsulinism from ISC stimulated LPL and CET by studying well-controlled IDDM patients after ISC and then 6 months after lowering systemic insulin levels by intraperitoneal (IP) insulin delivery. Although glycemic control (HbA1c IDDM, 6.9 +/- 1.7%; control, 4.5% to 8%) was excellent during ISC, CET was accelerated (P < .001) and both systemic insulin levels and LPL specific activity were increased (P < .05). Following IP, basal systemic insulin levels declined by more than one half (ISC, 8.22 +/- 6.5 versus IP, 2.77 +/- 2.4 microU/mL; mean +/- SD; P < .025), and both LPL and CET activities returned to normal. Plasma triglyceride, cholesterol, high-density lipoprotein-2 (HDL2) cholesterol, HDL3 cholesterol, cholesteryl ester transfer protein mass, and glycemic control (HbA1c, 6.3 +/- 0.8%) were unchanged and remained normal. These findings indicate that ISC is associated with high levels of basal CET and LPL. These alterations both appear to be closely linked to iatrogenic hyperinsulinemia resulting from ISC. The fact that they are both reversed when systemic insulin levels are reduced by IP suggests that insulin, acting through LPL, influences the nature of the interaction of the lipoproteins engaged in CET.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981182     DOI: 10.1161/01.atv.14.12.1933

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  8 in total

1.  Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues.

Authors:  Fariba Shojaee-Moradie; Michelle P Y Chan; Micayla A Telfer; Dietrich Brandenburg; Erik Sundermann; Heike Eckey; Jens Kleinjung; Achim Schüttler; Richard H Jones
Journal:  Biochem J       Date:  2004-07-01       Impact factor: 3.857

2.  Marine lipids normalize cholesteryl ester transfer in IDDM.

Authors:  J D Bagdade; M Ritter; P V Subbaiah
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

3.  Insulin does not regulate the promoter of cholesteryl ester transfer protein (CETP) in HIRc/pCETP-CAT cells.

Authors:  P S MacLean; H A Barakat
Journal:  Mol Cell Biochem       Date:  2000-08       Impact factor: 3.396

4.  A New Optimized Percutaneous Access System for CIPII.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2017-03-01

5.  Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes.

Authors:  Melanie Cree-Green; David M Maahs; Annie Ferland; John E Hokanson; Hong Wang; Laura Pyle; Gregory L Kinney; Martina King; Robert H Eckel; Kristen J Nadeau
Journal:  Pediatr Diabetes       Date:  2015-06-17       Impact factor: 4.866

6.  Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men.

Authors:  L Duvillard; E Florentin; M L Lalanne-Mistrich; J M Petit; S Baillot-Rudoni; A Brun-Pacaud; J M Brun; P Gambert; B Vergès
Journal:  Diabetologia       Date:  2005-05-26       Impact factor: 10.122

7.  DIETARY MANAGEMENT FOR DYSLIPIDEMIA IN LIVER TRANSPLANT RECIPIENTS.

Authors:  Andressa S Pinto; Marcio F Chedid; Léa T Guerra; Daiane D Cabeleira; Cleber D P Kruel
Journal:  Arq Bras Cir Dig       Date:  2016 Nov-Dec

8.  Lipoprotein metabolism in patients with type 1 diabetes under intensive insulin treatment.

Authors:  Alina C R Feitosa; Gilson S Feitosa-Filho; Fatima R Freitas; Bernardo L Wajchenberg; Raul C Maranhão
Journal:  Lipids Health Dis       Date:  2013-02-11       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.